SK Bioscience Co Ltd

SK Bioscience's capital structure is characterized by a debt-to-equity ratio of 0.26, indicating a relatively conservative leverage position. The company maintains a strong liquidity position with a current ratio of 3.82, supported by cash and equivalents of KRW 105.55 billion. However, the company's free cash flow is negative at KRW -225.54 billion, driven by capital expenditures of KRW -260.38 billion, which suggests ongoing investment in long-term growth. Profitability metrics show a challenging performance, with a net loss of KRW -57.42 billion and an operating loss of KRW -123.44 billion for the period. The return on equity (ROE) is negative at -3.21%, and the return on assets (ROA) is also negative at -1.94%, both significantly below the industry median for pharmaceuticals. Gross profit of KRW 75.92 billion reflects a narrow margin, which is a concern given the high R&D and production costs typical in the sector. The company's revenue is concentrated in a few key markets, with South Korea being the primary geographic source. While the company has expanded its international footprint, the majority of its revenue remains domestically generated, exposing it to regulatory and market risks in the Korean healthcare system. The lack of detailed segment reporting limits the ability to assess the performance of individual product lines or geographic regions. Looking ahead, SK Bioscience is expected to face continued financial pressure, with a net loss persisting into the next fiscal year. The company's revenue outlook is mixed, with analysts providing a wide range of price targets from KRW 23,000 to KRW 50,000, and a mean recommendation of 3.60, indicating a cautious stance. The company's capital expenditures suggest a focus on long-term growth, but the negative free cash flow indicates that this growth is being funded through operational cash flow rather than excess liquidity. Risk factors include the company's negative net cash position after subtracting total debt, which could limit its flexibility in responding to market changes or funding new projects. The risk of dilution is currently low, but the company's ongoing investment in R&D and capital expenditures may require additional financing in the future, potentially leading to share dilution. The company's liquidity risk is assessed as medium, reflecting the combination of strong current assets and negative free cash flow. Recent events include the publication of the latest financial results, which highlight the company's ongoing financial challenges. Analysts have issued a range of price targets, with the median at KRW 38,000 and the mean at KRW 37,250, suggesting a generally cautious outlook. The company has not disclosed any major new product launches or strategic partnerships in the most recent filings, which may indicate a period of consolidation or focus on existing product lines.